Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210391 · ClinicalTrials.gov registry record · NA
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 282
- Enrollment target
NCT01210391: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT01210391 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 282 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01210391, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 282 participants
- Enrollment target
Study Summary
The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.
Primary Outcome
Mean weight gain (g/day) from enrollment to 4 months of age.
Interventions
- OTHER Extensively hydrolyzed casein infant formula
- OTHER Extensively hydrolyzed whey infant formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-07 |
| Phase | NA |
What the finished NCT01210391 record still lists
NCT01210391 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Extensively hydrolyzed casein infant formula is the first listed.
NCT01210391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01210391 about?
NCT01210391 is a clinical study titled "Growth of Infants Fed an Extensively Hydrolyzed Infant Formula". The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.
What is the current status of trial NCT01210391?
This trial is currently completed. It is a NA study. The enrollment target is 282 participants. The study started on 2010-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01210391?
The interventions under investigation include: Extensively hydrolyzed casein infant formula (OTHER), Extensively hydrolyzed whey infant formula (OTHER).
Who is sponsoring clinical trial NCT01210391?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01210391's enrollment target sits among peer trials
282 379th of 2000 higher than 1,621 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia